An innovative dosimetric model for formulating a semi-analytical solution for the activity-volume relationship in prostate implants.
An innovative (and yet simple) dosimetric model is proposed that provides a semi-analytical solution to the total activity-volume relationship in ultrasound-guided transperineal prostate implant. This dosimetric model is based on 4 simple assumptions. First, the prostate target volume is approximated as a sphere. Second, the urethra is presumed to transverse through the center of the prostate target volume. Third, peripheral loading is applied as the seed-loading technique. Fourth, as the major innovation of the proposed model, the radial dose function of the Iodine-125 125I seed is forced to fit a simple power function of the distance r. Pursuant to the third assumption, the peripherally-loaded seeds also define a spherical volume defined as the loading volume w. Also pursuant to the fourth assumption, the radial dose function is expressed as 1.139*r(-0.474) for r = 1.5 to 2.5 cm. Thereafter, a simple analytical power-law equation, A = 1.630* w(0.825), for the relationship between the total activity A in mCi and the loading volume w in cc is derived for 125I monotherapy. Isodose plans for loading volumes corresponding to r = 1.5, 1.8, 2.2, and 2.5 cm were performed. The maximal isodose coverage volume maxV100 was calculated for each case and was found to be on the average 65% larger than the loading volume w. Matching prostate target volume V to the loading volume w therefore yields a generous implant (with a margin of approximately 3.3 mm). Conversely, matching the prostate target volume V to the maxV100 yields a tight implant (with 0.0 mm or no margin). Matching the prostate target volume V to a midpoint between the loading volume w and maxV100 yields a moderate implant (with approximately 1- to 2-mm margin). Three individual equations are derived for each type of implants: A = 1.630* V(0.825), A = 1.288* V(0.825), or A = 1.078 V(0.825) for generous, tight, or moderate implants, respectively. Patient data at the Chicago Prostate Cancer Center are found to support the above dosimetric model and the 3 semi-analytically derived equations. The above equations are also compared favorably with some of the previously published equations from other authors. These results support the efficacy of the proposed dosimetric model.